128 related articles for article (PubMed ID: 36208576)
1. Visible- and near-infrared hyperspectral imaging for the quantitative analysis of PD-L1+ cells in human lymphomas: Comparison with fluorescent multiplex immunohistochemistry.
Brunner A; Willenbacher E; Willenbacher W; Zelger B; Zelger P; Huck CW; Pallua JD
Spectrochim Acta A Mol Biomol Spectrosc; 2023 Jan; 285():121940. PubMed ID: 36208576
[TBL] [Abstract][Full Text] [Related]
2. Visible and Near-Infrared hyperspectral imaging (HSI) can reliably quantify CD3 and CD45 positive inflammatory cells in myocarditis: Pilot study on formalin-fixed paraffin-embedded specimens from myocard obtained during autopsy.
Brunner A; Schmidt VM; Zelger B; Woess C; Arora R; Zelger P; Huck CW; Pallua J
Spectrochim Acta A Mol Biomol Spectrosc; 2022 Jun; 274():121092. PubMed ID: 35257987
[TBL] [Abstract][Full Text] [Related]
3. Visible and near-infrared hyperspectral imaging techniques allow the reliable quantification of prognostic markers in lymphomas: A pilot study using the Ki67 proliferation index as an example.
Willenbacher E; Brunner A; Willenbacher W; Zelger B; Wolf D; Rogge D; Tappert M; Pallua JD
Exp Hematol; 2020 Nov; 91():55-64. PubMed ID: 32966868
[TBL] [Abstract][Full Text] [Related]
4. Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC.
Yeong J; Tan T; Chow ZL; Cheng Q; Lee B; Seet A; Lim JX; Lim JCT; Ong CCH; Thike AA; Saraf S; Tan BYC; Poh YC; Yee S; Liu J; Lim E; Iqbal J; Dent R; Tan PH
J Clin Pathol; 2020 Sep; 73(9):557-562. PubMed ID: 31969377
[TBL] [Abstract][Full Text] [Related]
5. Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers.
Sun Z; Nyberg R; Wu Y; Bernard B; Redmond WL
PLoS One; 2021; 16(2):e0247238. PubMed ID: 33596250
[TBL] [Abstract][Full Text] [Related]
6. Validation of multiplex immunofluorescence and digital image analysis for programmed death-ligand 1 expression and immune cell assessment in non-small cell lung cancer: comparison with conventional immunohistochemistry.
Wu J; Mao L; Sun W; Yang X; Wang H; Liu X; Chi K; Huang X; Lin D
J Clin Pathol; 2022 Jul; 75(7):452-458. PubMed ID: 33782193
[TBL] [Abstract][Full Text] [Related]
7. Analytical validation of automated multiplex chromogenic immunohistochemistry for diagnostic and predictive purpose in non-small cell lung cancer.
Ilié M; Beaulande M; Long-Mira E; Bontoux C; Zahaf K; Lalvée S; Hamila M; Benzaquen J; Cohen C; Berthet JP; Marquette CH; Lassalle S; Hofman V; Hofman P
Lung Cancer; 2022 Apr; 166():1-8. PubMed ID: 35134710
[TBL] [Abstract][Full Text] [Related]
8. A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies.
Batenchuk C; Albitar M; Zerba K; Sudarsanam S; Chizhevsky V; Jin C; Burns V
J Clin Pathol; 2018 Dec; 71(12):1078-1083. PubMed ID: 30275099
[TBL] [Abstract][Full Text] [Related]
9. Digital image analysis in pathologist-selected regions of interest predicts survival more accurately than whole-slide analysis: a direct comparison study in 153 gastric carcinomas.
Heo YJ; Lee T; Byeon SJ; Kim EJ; Shin HC; Kim B; Kang SY; Ha SY; Kim KM
J Pathol Clin Res; 2021 Jan; 7(1):42-51. PubMed ID: 32885920
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis.
Lu S; Stein JE; Rimm DL; Wang DW; Bell JM; Johnson DB; Sosman JA; Schalper KA; Anders RA; Wang H; Hoyt C; Pardoll DM; Danilova L; Taube JM
JAMA Oncol; 2019 Aug; 5(8):1195-1204. PubMed ID: 31318407
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
Hirsch FR; McElhinny A; Stanforth D; Ranger-Moore J; Jansson M; Kulangara K; Richardson W; Towne P; Hanks D; Vennapusa B; Mistry A; Kalamegham R; Averbuch S; Novotny J; Rubin E; Emancipator K; McCaffery I; Williams JA; Walker J; Longshore J; Tsao MS; Kerr KM
J Thorac Oncol; 2017 Feb; 12(2):208-222. PubMed ID: 27913228
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral CD39
Yeong J; Suteja L; Simoni Y; Lau KW; Tan AC; Li HH; Lim S; Loh JH; Wee FYT; Nerurkar SN; Takano A; Tan EH; Lim TKH; Newell EW; Tan DSW
J Thorac Oncol; 2021 Aug; 16(8):1349-1358. PubMed ID: 33975004
[TBL] [Abstract][Full Text] [Related]
13. Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma.
Huang S; Nong L; Liang L; Zheng Y; Wang W; Liu J; Li D; Li X; Wang Y; Zhang B; Li T
Cancer Med; 2019 Jul; 8(8):3831-3845. PubMed ID: 31150165
[TBL] [Abstract][Full Text] [Related]
14. Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas.
Coppock JD; Volaric AK; Mills AM; Gru AA
Hum Pathol; 2018 Dec; 82():282-288. PubMed ID: 30075155
[TBL] [Abstract][Full Text] [Related]
15. Immune Profiling of Advanced Thyroid Cancers Using Fluorescent Multiplex Immunohistochemistry.
Ahn J; Jin M; Song E; Ryu YM; Song DE; Kim SY; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
Thyroid; 2021 Jan; 31(1):61-67. PubMed ID: 32611231
[No Abstract] [Full Text] [Related]
16. Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization.
Humphries MP; Bingham V; Abdullahi Sidi F; Craig SG; McQuaid S; James J; Salto-Tellez M
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32365629
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 Multiplex and Quantitative Image Analysis for Molecular Diagnostics.
Abdullahi Sidi F; Bingham V; Craig SG; McQuaid S; James J; Humphries MP; Salto-Tellez M
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33374775
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer.
Jasani B; Bänfer G; Fish R; Waelput W; Sucaet Y; Barker C; Whiteley JL; Walker J; Hovelinck R; Diezko R
Diagn Pathol; 2020 Apr; 15(1):37. PubMed ID: 32303234
[TBL] [Abstract][Full Text] [Related]
19. Multiplex immunohistochemistry and high-throughput image analysis for evaluation of spatial tumor immune cell markers in human breast cancer.
Su T; Wang S; Huang S; Cai H; McKinley ET; Beeghly-Fadiel A; Zheng W; Shu XO; Cai Q
Cancer Biomark; 2022; 35(2):193-206. PubMed ID: 36093688
[TBL] [Abstract][Full Text] [Related]
20. Concordance of PD-L1 Expression Detection in Non-Small Cell Lung Cancer (NSCLC) Tissue Biopsy Specimens Between OncoTect iO Lung Assay and Immunohistochemistry (IHC).
Young S; Griego-Fullbright C; Wagner A; Chargin A; Patterson BK; Chabot-Richards D
Am J Clin Pathol; 2018 Aug; 150(4):346-352. PubMed ID: 30052717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
